| 摘要 |
The present invention relates to the formula described; wherein R1 denotes OH, C1-6-alkoxy or -O(C3-7)-cycloalkyl; R2 denotes C1-6-alkyl; R3 denotes C1-6-alkyl,-(CH2)1-2-aryl,-(CH2)1-2-heterocyclyl, -CH2CH=C(R6)2, pr -CH2-(C3-7)-cycloalkyl; R4 and R5, identically to or different from each other, denote H, Cl, F, CF3, C1-6-alkyl, OH, C1-6-alkoxy. O-(C3-7)-cycloalkyl, -(CH2)0-2-aryl, -O-(CH2)0-2-aryl, a,b- or b, g-benzo which are unsubstituted, mono- or disubstituted with Cl, F, CF3, OH, C1-6-alkyl or C1-6-alkoxy or -CON(R6R7); R6 denotes H or C1-6-alkyl; R7 denotes H, C1-6-alkyl, -(CH2)0-2-aryl or CH2-(C3-C7)-cycloalkyl or R6 and R7 taken together denote (-CH2-)5-7 or (CH2)2-O-(CH2)2-; X denotes O, S, SO or SO2 Y denotes -(CH2)1-2-, -CH2-C(CH3)2- or -C(CH3)2-; Or pharmaceutically acceptable salts thereof. The underlying object of the present invention is therefore to identify substances having analgesic effect, the biological efficacy of which is brought about, having predominantly or in part, via d-opiate receptors. These requirements have been fulfilled by the substituted heterocyclic benzocyclalkene compounds of the present invention.
|
